Skip to main content
Signal8

Swedish Orphan Biovitrum AB (BIOVF)

Sector: Medical - Pharmaceuticals

Industry: Medical - Pharmaceuticals

Swedish Orphan Biovitrum AB logo

Swedish Orphan Biovitrum AB

OTC:BIOVFHealthcare
CLOSED
Mkt Cap$17.77B
EV-
Float181.53M
O/S348M
VOL100 sh
$ Vol$5K
Inst Own-
SI0.2%
Net Cash/Sh-
EarningsFeb 4 · in 3mo
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 202651.0551.0551.0551.05100
Oct 23, 202645.7245.7245.7245.72110
Oct 21, 202646.0046.0046.0046.00102
Oct 6, 202642.8042.8042.8042.8020,000
Analyst Coverage
Analyst Coverage
ConsensusHold
Price Target
Not available
Ratings Distribution
BUY
0
HOLD
1
SELL
0
TOTAL1
About

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

The company operates through three segments: Haematology, Immunology, and Specialty Care.

It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocytopenia and thrombocytopenia; Elocta/Eloctate for the treatment and prophylaxis of bleeding in patients with haemophilia A; Gamifant for treating hemophagocytic lymphohistiocytosis; Kineret for the treatment of cryopyrin-associated periodic syndrome, rheumatoid arthritis, familial Mediterranean fever, deficiency of interleukin-1 receptor antagonist, and systemic juvenile idiopathic arthritis; Orfadin for hereditary tyrosinemia type 1 and alkaptonuria; Synagis for the prevention of serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children; VONJO, a kinase inhibitor indicated for the treatment of post-polycythemia vera or post-essential thrombocythemia myelofibrosis; and Zynlonta for treating adult patients with relapsed or refractory diffuse large and high grade B-cell lymphoma.

The company also provides other medicines, such as Akynzeo, Jyseleca, Tegsedi, and Waylivra, as well as develops drug substances for ReFacto AF/Xyntha for Pfizer.

The company has collaboration agreements with Sanofi, Apellis Pharmaceuticals, Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc.

The company was incorporated in 1939 and is headquartered in Stockholm, Sweden.

Key Metrics
Market Cap$17.77B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 348.00M shares outstanding

SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeOTC
CountrySESE
IPO Date-
Shares Outstanding348.00M
Authorized Shares
Float181.53M
52-Week Range
Volume
Average Daily Volume--

30d Avg

--

60d Avg

--

90d Avg

--

Earnings
Dividend History
No dividend history available